Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD08 in HPV-16/18 Related Cervical HSIL
NCT06276101Phase 1Completed
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NWRD08 in cervical squamous intraepithelial lesion (SIL), sponsored by Newish Technology (Beijing) Co., Ltd. Primary endpoints: Safety at 36 weeks and Dose-limiting toxicity at 28 days. Started May 2024; status: completed.
02
Drugs
NWRD08
03
Conditions
cervical squamous intraepithelial lesion (SIL)
Beyond the preview
Go deeper on NCT06276101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276101.